Beta DrugsNSE:BETA +8.06%91 PS Ratio is 13.24 as of Jul. 11, 2026, which is 43% above its 10-year median of 9.24. GuruFocus rates NSE:BETA with a GF Score™ of 91/100 and a GF Value™ of ₹1,975.60 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 952 Drug Manufacturers companies, Beta Drugs ranks worse than 87.92% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Beta Drugs's share price is ₹2366.80.
Beta Drugs's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹178.80. Hence, Beta Drugs's PS Ratio for today is 13.24.
Good Sign:
Beta Drugs Ltd stock PS Ratio (=5.51) is close to 2-year low of 5.51.
The historical rank and industry rank for Beta Drugs's PS Ratio or its related term are showing as below:
NSE:BETA'
s PS Ratio Range Over the Past 10 Years
Min: 5.73 Med: 9.24 Max: 21.3
Current: 12.07
During the past 13 years, Beta Drugs's highest PS Ratio was 21.30. The lowest was 5.73. And the median was 9.24.
NSE:BETA's PS Ratio is ranked worse than 87.92% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.295
vs NSE:BETA: 12.07
Beta Drugs Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Beta Drugs was 5.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 19.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 26.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 30.20% per year.
During the past 13 years, Beta Drugs's highest 3-Year average Revenue per Share Growth Rate was 477.60% per year. The lowest was 19.00% per year. And the median was 35.70% per year.
Back to Basics: PS Ratio
Beta Drugs (NSE:BETA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Beta Drugs PS Ratio Related Terms
Beta Drugs PS Ratio Historical Data
* Premium members only.
The historical data trend for Beta Drugs's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's PS Ratio distribution charts can be found below:
* The bar in red indicates where Beta Drugs's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Beta Drugs's Share Price of today is ₹2366.80. Beta Drugs's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹178.80.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Beta Drugs (NSE:BETA) has a PS Ratio of 13.24 as of Jul. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Beta Drugs and its competitors. This is 43% above median its historical median of 9.24. Over the past decade, Beta Drugs' PS Ratio has ranged from 5.73 to 21.30. According to the industry distribution chart, Beta Drugs ranks #837 out of 952 companies in the Drug Manufacturers industry, placing it in the top 87.9%.
Is Beta Drugs' PS Ratio too high?
Beta Drugs' current PS Ratio of 13.24 is 43% above median its 10-year median of 9.24. Over the past 10 years, this metric has ranged from a low of 5.73 to a high of 21.30. The Drug Manufacturers industry median PS Ratio is 2.30. Beta Drugs' value of 13.24 is 476.9% above this industry median. Based on the distribution chart, Beta Drugs ranks #837 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Beta Drugs has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #837 out of 952 companies for PS Ratio. This places Beta Drugs in the lower half of its industry. The industry median PS Ratio is 2.30. Beta Drugs' value of 13.24 is 476.9% above this benchmark. Historically, Beta Drugs' own PS Ratio has ranged from 5.73 to 21.30 over the past decade. While the company's 10-year median is 9.24 vs. the industry median of 2.30, Beta Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Drugs's current PS Ratio of 13.24 is 476.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Beta Drugs and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current PS Ratio is 13.24, which is 43% above median its own 10-year median of 9.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,975.60, compared to a current price of ₹2,366.80 — trading 19.8% above its estimated fair value. The current PS Ratio is 13.24, which is 43% above median its 10-year median of 9.24 and 476.9% above the Drug Manufacturers industry median of 2.30. Beta Drugs' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current PS Ratio is 13.24 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued.
The current stock price of ₹2,366.80 is trading 19.8% above its estimated GF Value™ of ₹1,975.60.
GuruFocus considers Beta Drugs to be Modestly Overvalued.
Key valuation signals for NSE:BETA:
PS Ratio: 13.24 (43% above median its 10-year median of 9.24)
GF Value™: ₹1,975.60 vs. price of ₹2,366.80 (19.8% above fair value)
Industry Position: 476.9% above the Drug Manufacturers median (#837 of 952)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
91GF Score
Get the complete analysis for NSE:BETA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
